Nath Bio-Genes (India)'s Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Nath Bio-Genes (India) Ltd reported a 84.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 41.9%.
- Its expenses for the quarter were down by 83.0% QoQ and up 36.0% YoY.
- The net profit decreased 92.6% QoQ and increased 147.7% YoY.
- The earnings per share (EPS) of Nath Bio-Genes (India) Ltd stood at 1.4 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 45.78 | 285.46 | 32.27 | -84.0% | 41.9% |
Total Expenses | 42.40 | 249.60 | 31.18 | -83.0% | 36.0% |
Profit Before Tax | 5.46 | 35.88 | 1.09 | -84.8% | 400.9% |
Tax | 0.64 | 0.66 | -0.03 | -3.0% | -2233.3% |
Profit After Tax | 2.75 | 37.28 | 1.11 | -92.6% | 147.7% |
Earnings Per Share | 1.40 | 19.58 | 0.53 | -92.8% | 164.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Nath Bio-Genes (India) Ltd is a company operating in the agriculture sector, primarily involved in the production and distribution of seeds. The company specializes in hybrid seeds for various crops, including cotton, paddy, and vegetables, among others. Nath Bio-Genes focuses on research and development to improve crop yields and cater to the needs of the farming community. Recent developments in the seed industry and agricultural policies could have impacts on the company's operations, but specific recent developments for Nath Bio-Genes are not available based on the provided data.
Revenue
For the second quarter of the fiscal year 2026, Nath Bio-Genes reported a total income of ₹45.78 crores. This reflects a significant decrease of 84.0% in quarter-over-quarter (QoQ) comparison with the first quarter of FY26, where the total income was ₹285.46 crores. However, when compared year-over-year (YoY) to the second quarter of FY25, where the total income was ₹32.27 crores, there was an increase of 41.9%. These changes indicate fluctuations in income over the quarters and a notable increase compared to the previous year.
Profitability
The company's profit before tax for Q2FY26 was ₹5.46 crores, a decrease of 84.8% from ₹35.88 crores in Q1FY26. Year-over-year, this represents a substantial increase of 400.9% from ₹1.09 crores in Q2FY25. The profit after tax in Q2FY26 was ₹2.75 crores, showing a significant decrease of 92.6% from ₹37.28 crores in the previous quarter. Compared to the same quarter last year, the profit after tax increased by 147.7% from ₹1.11 crores. The earnings per share for this quarter stood at ₹1.40, down 92.8% from ₹19.58 in Q1FY26, but an increase of 164.2% from ₹0.53 in Q2FY25.
Operating Metrics
Total expenses for Nath Bio-Genes in Q2FY26 amounted to ₹42.40 crores, a reduction of 83.0% from ₹249.60 crores in Q1FY26. Compared to Q2FY25, total expenses increased by 36.0% from ₹31.18 crores. The tax expense for Q2FY26 was ₹0.64 crores, reflecting a slight decrease of 3.0% from ₹0.66 crores in the previous quarter, and a considerable change from a negative tax of ₹-0.03 crores in Q2FY25, marking a YoY increase of 2233.3%. These metrics highlight the company's operational cost management and tax obligations over the periods analyzed.